Adjuvant Pembrolizumab Prolongs Overall Survival in Clear Cell RCC – Renal and Urology News
One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient.